Innovent Biologics (STU:6IB) Effective Interest Rate on Debt % : 2.73% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Innovent Biologics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was €12.4 Mil. Innovent Biologics's average total debt for the quarter that ended in Dec. 2023 was €455.0 Mil. Therefore, Innovent Biologics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 2.73%.

Innovent Biologics Effective Interest Rate on Debt % Historical Data

The historical data trend for Innovent Biologics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Effective Interest Rate on Debt % Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

7.20

6.54

3.48

3.51

2.81

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial										3.35	3.41	3.74	2.94	2.73

Competitive Comparison of Innovent Biologics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Innovent Biologics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovent Biologics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Effective Interest Rate on Debt % falls into.

Innovent Biologics Effective Interest Rate on Debt % Calculation

Innovent Biologics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -12.666	/	( (437.155	+	464.976)	/ 2 )
=	-1 * -12.666	/	451.0655
=	2.81 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	313.342	+	123.813
=	437.155

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	308.252	+	156.724
=	464.976

Innovent Biologics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Jun. 2023 )	+	Total Debt (Q: Dec. 2023 ))	/ count )
=	-1 * -12.414	/	( (444.95	+	464.976)	/ 2 )
=	-1 * -12.414	/	454.963
=	2.73 %

where

	Total Debt (Q: Jun. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	383.457	+	61.493
=	444.95

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	308.252	+	156.724
=	464.976

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Innovent Biologics (STU:6IB) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Innovent Biologics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (STU:6IB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (STU:6IB) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 01801:Hong Kong

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (STU:6IB) Headlines

No Headlines